- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01116466
Clinical Study to Evaluate the Implantation of the ActiGait Drop Foot Stimulator System
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- have a single sided hemiparesis persisting for more than 6 months due to a cerebro-vascular accident (CVA).
- be fully grown-up.
- have the ability to walk 20 meters in less than 2 minutes with or without walking aid but without the help of another person.
- have a reduced speed of walking.
- have the ability to stand upright with both heels touching the floor while hip and knee are in neutral position.
- have a passive range of movement of the affected ankle joint of at least 30 degrees.
- have a positive response to surface electrical stimulation of the peroneal nerve - i.e. muscle contraction which results in dorsiflexion of the ankle and improved gait.
- male or female older than 18 years of age.
- have signed written Informed consent to participate in the study.
- is willing and able to follow all study procedures including attendance at clinics for scheduled study visits.
Exclusion Criteria:
- peripheral nerve damage of the affected leg.
- severe or uncontrolled diabetes with peripheral nerve involvement.
- poor skin condition on the affected leg.
- a thickness of subcutaneous fat exceeding 3.5 cm in the region of the implant.
- inability to walk 100 meters without stopping prior to CVA (with or without a walking aid, but without the help of another person).
- poorly controlled epilepsy.
- need of Ankle Foot Orthosis (AOF) to maintain ankle stability.
- concomitant medical and psychological conditions which would limit the success of the ActiGait® system such as: active degenerative diseases of the back and lower limbs, visuo-spatial neglect, or drug abuse, personality disorders or poor cognitive function.
- concomitant medical and psychological conditions which would compromise the safety of the patient in connection with the implantation and use of the ActiGait system, such as: severe cardiac disease, uncontrolled hypertension or history of malignancy within the preceding five years.
- other active implanted devices such as demand pacemakers or implanted defibrillators, as mutual electromagnetic interference may distort the efficacy of both systems and expose the patient to dangerous situations.
- history of falls greater than once a week.
- pregnancy and lactation. Women of childbearing potential must maintain effective contraception during the study period, as judged by the investigator.
- previous participation in this study
- participation in an investigational drug trial within 4 weeks prior to enrolment.
- requirement of an interpreter
- use of external FES system to assist walking four weeks prior to enrolment
- MRI of the affected thigh that is inconsistent with safe implantation of the ActiGait
- history of falls greater than once a week.
- pregnancy and lactation. Women of childbearing potential must maintain effective contraception during the study period, as judged by the investigator.
- previous participation in this study.
- participation in an investigational drug trial within 4 weeks prior to enrolment.
- requirement of an interpreter.
- anatomic situation of the common peroneal nerve identified by pre-surgical MRI that could compromise the success of ActiGait).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ActiGait
Receiving ActiGait - implantable drop foot stimulator
|
ActiGait - implantable drop foot stimulator
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Distance Walked in 6 Minutes
Time Frame: Baseline, 6 and 12 weeks post-implantation
|
The test assesses distance walked over 6 minutes as a sub-maximal test of aerobic capacity (endurance).
At baseline this test was done with subject's conventional walking aid.
At 6 and 12 weeks post-implantation this was done with and without stimulation.
|
Baseline, 6 and 12 weeks post-implantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Walking Speed During 10 Meter Gait Test
Time Frame: Baseline, 6 and 12 weeks post-implantation
|
The test assesses walking speed in meters per second over a short duration.
At baseline this test was done with subject's conventional walking aid.
At 6 and 12 weeks post-implantation this was done with and without stimulation.
|
Baseline, 6 and 12 weeks post-implantation
|
Canadian Occupational Performance Measure (COPM) Score
Time Frame: Baseline,12 weeks post-implantation
|
A semi-structured interview is conducted in order to identify subject's limitations with daily occupations of importance in categories self-care, productivtiy or leisure.
The subject is then asked to rate the imporance of each of the occupations using a 10-point rating scale.
Afterwards the subject chooses up to 5 of the most important occupations (problems) (basis for identifying intervention goals).
The subject is asked to use a 10 point scale to rate level of performance and satisfaction with performance for each of the five identified problems.
Average COPM performance score and satisfaction score are calculated.
The scores range between 1 and 10, where 1 indicates poor performance and low satisfaction, respectively, while 10 indicates very good performance and high satisfaction.
|
Baseline,12 weeks post-implantation
|
Four Square Step Test (FSST)
Time Frame: Baseline, week 12 post-implantation
|
It is a test of dynamic balance that clinically assesses the person's ability to step over objects forward, sideways, and backwards.
The patient's time to perform the test is measured which shorter time representing better performance.
At baseline this test was done with subject's conventional walking aid.
At 12 weeks post-implantation it was done with and without stimulation.
|
Baseline, week 12 post-implantation
|
Nerve Conduction Velocity of the Peroneal Nerve
Time Frame: Baseline, week 12 post-implantation
|
Measured: Nervus peroneus communis (CPN) and Nervus peroneus superficialis (SPN)
|
Baseline, week 12 post-implantation
|
Change in MRI of Affected Leg and Implant Post-implantation
Time Frame: Week 2 post-implantation
|
MRI will be conducted to evaluate the impact of the implant on the common peroneal nerve (e.g. positioning of the nerve cuff along the nerve, path of the lead wire and the common peroneal nerve, estimation of the cross-sectional area of the common peroneal nerve compared to the pre-operative MRI recording, etc.). The outcome will be quantified by surgeon's judgement whether the final implant position is consistent with safe application of the ActiGait® implant as described in the manufacturer's surgical manual. Number of safe and successful implantations will be counted. |
Week 2 post-implantation
|
Collaborators and Investigators
Investigators
- Principal Investigator: David Liebetanz, MD, Medical University Georg-August-University Goettingen, Germany
- Principal Investigator: Veit Rhode, MD, Medical University Georg-August-University Goettingen, Germany
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PB-SA844-100
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
Clinical Trials on ActiGait
-
Medical University of ViennaCompletedGait, Hemiplegic